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Photodynamic Therapy for Obstructive Esophageal
Malignancies
JAMES S. McCAUGHAN, J,.*
Grant Medical Center, 323 E. Town Street, Columbus, OH 43215, USA
Objectives Determine factors affecting survival rates, benefits and complications of
patients with obstructive esophageal cancer treated with photodynamic therapy (PDT).
Methods From 1982 to January 1998, we used PDT to treat 140 patients with ob-
structive adeno or squamous carcinoma and evaluated survival up to November 1998. All
patients had failed, refused, or were ineligible for surgery, ionizing radiation or chemo-
therapy. The effect of different variables on survival was estimated using multivariate
analysis. The Karnofsky Performance Status (KPS), weight, diet and complications
were recorded and biopsies and brushings were taken at each endoscopy. At the begin-
ning and end of each endoscopy the minimal diameter open of the esophagus, and the
length, thickness and color of the tumor were recorded. Edema, exudate, bleeding, and
mucositis were evaluated and recorded on an ordinal scale.
Results The only significant variable affecting survival was the clinical stage. The
median survival after PDT for all patients was 6.5 months (mean= 13.9). Kaplan-
Meier survival after PDT curves were statistically significantly different when stratified
by the clinical Stage at the time ofPDT (p < 0.0001). Median survival (months) were for:
Stage I: 56; Stage II 12; Stage III: 6.5; Stage IV--3.5. Analysis of each individual
stage showed the KPS was the only confounding variable with a statistically significant
effect on survival after PDT and this was only for Stages III and IV. The most signifi-
cant effect occurred when the KPS was >_ 70. For Stage III the median survival when
the KPS was _> 70 was 7.7 months and for a KPS < 70 it was 5.0 months (p :0.0001).
For Stage IV the median survival when the KPS was >_ 70 was 5.5 months and for a
KPS < 70 it was 2.5 months (p 0.0002). The mean minimum diameter open before
PDT was 6.2mm (median 6.0mm) and at the end of the PDT treatment endoscopy
11.1mm (median 12.0mm) for a mean increase in the minimum diameter open of 4.9mm
(median 5.0mm) This was statistically significant using paired t-tests (p < 0.0001).
Conclusions Photodynamic therapy for esophageal carcinoma caused minimal com-
plications and procedure related mortality. Complete obstruction can be relieved by the
end of the PDT endoscopy. The length of palliation for "non-curative" patients was
equal to or better than that reported historically for most other treatment regimens.
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Abbreviations." PDT, photodynamic therapy; KPS, Karnofsky performance status;
DHE, dihematoporphyrin ether; LMB, left main bronchus
INTRODUCTION
The use of selective photodynamic therapy (PDT)
to treat malignant tumors is based on three obser-
vations: (1) after being injected intravenously, the
photosensitizer disseminates to all cells; (2) due to
differences in vascular and lymphatic clearance
from tumors, and retention of the photosensitizer
by the tumor cells, the photosensitizer is selectively
retained in the tumor cells and interstitial tissue of
the tumor so that after two or three days there is a
greater concentration of the photosensitizer in the
tumors than in the adjacent normal tissue; (3) the
photosensitizer will absorb light energy and produce
singlet oxygen which then destroys the tumor. Since
there is less photosensitizer in the adjacent tissue, it
will react less. We report here our experience using
PDT to treat patients with obstructive esophageal
cancer.
MATERIALS AND METHODS
In a prospective study from 1982 to January 1998
we used PDT to treat 140 patients with obstruc-
tive esophageal carcinoma and evaluated their sur-
vival up to November 1998. Entry criteria were a
histologic diagnosis of adeno or squamous cell
carcinoma of the esophagus and failure of conven-
tional treatment or ineligibility for them because of
medical status. There was 100% follow up.
Their ages ranged from 35 to 91 with a mean of
68 and median of 67 years. One hundred and forty
patients (95 adenocarcinoma and 45 squamous) had
varying degrees of obstruction and difficulty swal-
lowing with a mean minimum diameter of 6.2mm
(median 6.0 ram).
All patients were clinically staged at the time of
their PDT using the TNM system [1] based on
the history, physical examination, bronchoscopy,
esophagoscopy, barium esophagrams and CT scans
of the chest and abdomen. Fourteen were Stage I
(13 adeno, squamous), 23 were Stage II (18 adeno,
5 squamous), 51 were Stage III (28 adeno, 23
squamous), and 52 were Stage IV (36 adeno, 16
squamous).
The Karnofsky Performance Status (KPS) [2],
weight, diet and complications were recorded and
biopsies and brushings were taken at each endo-
scopy. At the beginning and end ofeach endoscopy
the minimal diameter open of the esophagus, and
the length, thickness and color of the tumor were
recorded. Edema, exudate, bleeding, and mucositis
were evaluated and recorded on an ordinal scale.
Photodynamic therapy was performed using
630nm light generated by either an argon dye laser
system (Spectra Physics) or a double frequency
YAG-dye laser system (Laserscope) as the activator
and delivered through cylinder diffusing tip quartz
fibers passed through the biopsy channel of a
flexible endoscope. When possible the diffuser tip
was inserted into the tumor. Otherwise, itwas placed
along side of the tumor.
Initial treatments were performed using hemato-
porphyrin derivative as the photosensitizer but for
the last 14 years we have used dihematoporphyrin
ether (DHE, Photofrin; Quadra Logic Techno-
logies, Vancouver, B.C.) injected intravenously
one to three days before the treatment.
Various photosensitizer doses, day of treatment
after injection, light power densities, and light doses
were evaluated [3-8]. Analyses of the results from
these various parameters lead us to now use 60mg
of DHE per meter squared of body surface [9];
power densities of 400mW per centimeter of dif-
fusing fiber; light doses of 300 J per centimeter of
diffusing fiber, interstitial treatment of the tumor if
possible, and treatment 1-3 days after injection of
the photosensitizer.
Two to three days after PDT, esophagoscopy was
repeated and necrotic tissue mechanically removed.
One month after PDT a repeat endoscopy was
done and residual tumor was treated following
another injection of photosensitizer. Patients werePDT FOR OBSTRUCTIVE ESOPHAGEAL CANCER 169
periodically endoscoped and retreated for sympto-
matic residual tumor.
Statistical Analyses
Statistical analyses were performed using Super-
ANOVA, StatView, and Survival Tools (Abacus
Concepts, Inc., Berkeley, CA). All statistics used
95% confidence limits. Disease specific survival
times in months were calculated from the time
of their first PDT to the end point of November
1998 using Kaplan-Meier tables and curves. The
Breslow-Gehan-Wilcoxon test was used to com-
pare the significance of differences of survival dis-
tributions because it is more likely to detect early
differences than logrank tests and most of the
deaths occur early in all series ofesophageal cancer.
Cox proportional hazards tests were used to
estimate the effects of different variables on the
length of survival.
Paired t-tests were used to evaluate the increase in




The effect of different variables on survival of
140 patients with obstructive adeno or squamous
carcinoma after PDT was estimated using multi-
variate analysis. A model of the effects of age, sex,
race, KPS, day of treatment, histology, location of
tumor, length of tumor, minimum diameter of
esophagus open and clinical Stage showed the
only statistically significant variable was the Stage
(p 0.0008). The Global likelihood ratio for the
model was significant (p < 0.0001).
The median survival after PDT for all patients
was 6.5 months (mean= 13.9). Kaplan-Meier
survival after PDT curves were statistically signifi-
cantly different when stratified by the clinical Stage
at the time of PDT (p < 0.0001). Median survival
(months) were for: Stage I 56; Stage II 12; Stage
III --6.5; Stage IV-- 3.5 (Fig. 1).
Analysis ofeach individual stage showed the KPS
was the only confounding variable with a statisti-
cally significant effect on survival after PDT, but
only for Stages III and IV. The most significant
effect occurred when the KPS was >_ 70. For Stage
III the median survival when the KPS was > 70
was 7.7 months and for a KPS < 70 it was 5.0
months (p 0.0001). For Stage IV the median
survival when the KPS was > 70 was 5.5 months
and for a KPS < 70 it was 2.5 months (p- 0.0002).
Increase in Diameter Open at End of PDT
The mean minimum diameter open beforePDT was
6.2mm (median 6.0mm) and at the end of the PDT
treatment endoscopy 11.1 mm (median 1-2.0mm)
for a mean increase in the minimum diameter open
of 4.9mm (median 5.0mm). This was statistically
significant using paired t-tests (p < 0.0001).
Complete Obstruction of Esophagus
Twenty-five patients were completely obstructed.
The mean diameter open before PDT was 0.89mm
(median 0mm) and at the end ofPDT the mean and
median diameter open were 10.0mm (Fig. 2).
Complications
Transient elevations of the WBC and temperature
frequently developed immediately after PDT. Uni-
lateral or bilateral pleural effusions may occur over
several days but these spontaneously resolved.
Four patients had pulmonary complications after
PDT (infiltrates 2, aspiration pneumonia 1, pul-
monary edema 1; all resolved).
Four patients developed fistulae related to PDT
(two trachea, two LMB). All had squamous cell
cancer. One had visible tumor in the LMB before
PDT. Two were Stage III and two Stage IV. One
died from GI bleeding after insertion of an
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FIGURE Kaplan-Meier cumulative survival curves for patients with obstructive carcinoma of the esophagus treated with
photodynamic therapy stratified by their clinical stage at the time of PDT.
disease. Treatment before PDT consisted of: exter-
nal radiation to one; brachytherapy andYAG laser
to one; brachytherapy, chemotherapy and immuno-
therapy to one; and external radiation, chemo-
therapy andYAG laser to one.
Four patients developed strictures after PDT. All
were manageable with dilation.
Solar photosensitivity of the skin may last for up
to 8 weeks after the injection ofDHE. Five patients
developed erythema and itching on the hands
and/or face from sun exposure. They all resolved
spontaneously. Three patients developed edema of
the hands and one of the face. These completely
resolved over a few days with oral steroids. With
careful increasing sun exposure and repeated
instructions, there have not been any serious
photosensitivity reactions to the sun.
DISCUSSION
The most significant variable affecting the length of
survival in this series was the stage of the disease.
When staged, there was no statistically significant
difference due to age, sex, race, day of treatment,
length of tumor, minimal diameter of esophagus
open, or location of tumor. There was no statisti-
cally significance difference in the survival distribu-
tions within each stage between adenocarcinoma
and squamous cell carcinoma. However, within
Stages III and IV a KPS above or equal to 70 was
a significant favorable prognosticator and should be
considered in comparing survival rates from differ-
ent treatment regimens for these stages.
Photodynamic therapy for esophageal carci-
noma caused minimal complications and procedurePDT FOR OBSTRUCTIVE ESOPHAGEAL CANCER 171
FIGURE 2 Complete obstruction of esophagus by squamous cell carcinoma opened at the end of PDT endoscopy and one
month after PDT.
related mortality. The duration of palliation for
"non-curative" patients was equal to or better than
that reported historically for most other treatment
regimens [10].
Current Technique
We use general endotracheal anesthesia with a
7.5mm endotracheal tube. After intubation the
patient is put in high semi-Fowler’s position and
continuous oral suction is used to minimize aspira-
tion. If needed we use teflon guide wires and an
image intensifier to guide the scope or for use during
dilation with Savory or balloon dilators. PDT is
performed interstitially when possible. It is better to
under-treat than over-treat. Surface PDT is done
retrogradely using 2.5 cm diffusing tips. The tip is
moved back 3 cm to perform successive treatments
to minimize overlap. Although 300 J/CF is used for
completely circumferential tumors, we use only
200J/F if it appears non-tumor mucosa will be
exposed to the light, such as at the ends ofthe tumor.
A repeat esophagoscopy and dilation is done two
days after PDT but we rarely retreat at this time.
Patients are rescoped one month after PDT and we
may retreat at this time without another injection
[11]. At this time we use 300J/CF even on the
"normal" mucosa.
Comparison of Survival from other
Treatment Regimens
In a retrospective analysis ofsurvival from diagnosis
of 268 patients with carcinoma of the esophagus
Oliver et al. [12] found the overall median survival
(months) stratified by primary treatment was:
surgery 9.8; radical X-ray 6.3; intubation 3.3;
palliativeradiotherapy 2.7months.Unfortunately172 J.S. McCAUGHAN, Jrt.
they were not staged but only 34% were eligible for
surgery with an operative mortality of9%. Intuba-
tion had a mortality of 15%.
Fok et al. [13] compared patients that had
radiation treatment after surgery with those who
only had surgery. The median survivals (months)
were: curative resection 21; curative resection with
radiation 15; palliative resection 12; palliative
resection with radiation 7.
Urba et al. [14] reported a median survival of 11
months for 24 patients with adenocarcinoma of the
esophagus treated with preoperative chemotherapy
and radiation. Twenty-two were Stage II, one Stage I
and one Stage III.
Poplin et al. [15] reported on 106 patients with
squamous cell carcinoma of the esophagus regis-
tered into a study combining preoperative chemo-
therapy and external radiation with an overall
median survival of 12 months and an 11% operative
mortality.
LePrise et al. [16] reported preoperative chemo-
therapy and radiation (CRT) did not change the
operative mortality or survival time for patients
with Stages I and II squamous cell carcinoma of
the esophagus. The operative mortality was 8.5%
for CRT and 7% for without CRT. The median
survival was 10 months for both groups.
Skinner et al. [17] reported the median survival
of those patients chosen for "standard esopha-
gectomy" for palliation because ofextensive disease
was 8 months.
Law et al. [18] reported median survivals after
palliative resection of7 months for 236 patients with
squamous cell and 8 months for 57 patients with
adenocarcinoma.
We also treated 33 patients with theYAG laser for
esophageal obstruction [8] and compared our results
with PDT. PDT is easier to perform thanYAG laser
treatments. There is less possibility of burning a
hole in the tissue withPDT. On occasion, it is impos-
sible to get theYAG laser in position to safely treat
the tumor with the YAG because of the anatomy.
Cervical lesions are difficult to treat with the YAG
laser because one may not be able to keep the
endoscope in the esophagus. The PDT diffuser tip
can be inserted into or along side of the tumor and
the treatment performed blindly. Blind treatment
with the YAG laser invites disaster. It is difficult to
treat the tumors with the YAG laser antegradely
because the charred, burned tissue swells andmakes
it difficult to find the correct path for distal lasering.
Completely obstructed hard tumors that cannot be
dilated can be treated blindly with PDT, and they
soften by the end of treatment. PDT also treats
submucosal spread that is not visible and can be
used to treat small mammary-like tumors, whereas
the YAG might burn through the esophagus.
Exophytic lesions that are large or very bloody are
better treated with the YAG. Debulking large
tumors and treating the residual tumor a few weeks
later with PDT utilizes the advantages of both
techniques [19].
Barrett’s Dysplasia and Early Stage
Adenocarcinoma
The incidence of adenocarcinoma of the esophagus
and Barrett’s esophagus has been increasing since
the early 1980s [20-24].
At the same time the management of reflux
esophagitis changed dramatically with introduction
of histamine H2 receptor antagonists in 1977
cimetidine (Tagamet), 1983 ranitidine hydrochlor-
ide (Zantac), and 1986 famotidine (Pepsid). Gastric
acid pump inhibitors were then approved in 1989
omeprazole (Prilosec) and 1995 lansoprazole (Prev-
acid). Prior to these drugs, patients with symptom-
atic hiatal hernias had them surgically repaired but
with the introduction of these medications the
number of operations markedly decreased. Medical
management may relieve the symptoms, but it does
not correct the reflux nor cause the Barrett’s
metaplasia to return to normal squamous mucosa.
Once Barrett’s metaplasia has started, the reflux
repair and medications will not stop the devel-
opment of the carcinoma. Most adenocarcinomas
of the esophagus arise in Barrett’s metaplasia
[21,23,25,26]. Most Barrett’s are caused by acid
reflux [27,28]. Most reflux is due to hiatal hernias
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Overholt and Panjehpour [33] reported a75-80%
reduction of dysplasia in 36 patients with Barrett’s
treated with PDT with DHE. Ten had complete
replacement with squamous epithelium and 14
patients with stage I cancer had complete destruc-
tion of their tumors.
After PDT, the Barrett’s mucosa becomes nec-
rotic and is replaced with squamous epithelium.
However, two of our patients with stage I adeno-
carcinoma associated with Barrett’s metaplasia and
hiatal hernia had a complete response and normal
squamous epithelium 3 months after PDT, but
developed recurrence of the Barrett’s mucosa at 10
and 15 months, in spite ofmedicalmanagement with
omeprazole. The hiatal hernias were not repaired.
Biddlestone et al. [34] found histologic residual
glandular mucosa, non-neoplastic and dysplastic,
beneath squamous epithelium after acid suppres-
sion and laser and photodynamic therapy indicat-
ing the requirement for histologic confirmation of
endoscopically suspected complete squamous re-
epithelialization with sufficiently deep biopsies.
Advantages ofPDT for Barrett’s are: no procedure
related mortalities, it can be repeated indefinitely,
and the survival rate appears to be as good as
surgery.
We suggest: Symptomatic hiatal hernia without
Barrett’s should be surgically repaired. Current
Barrett’s metaplasia should be treated with PDT
to destroy the Barrett’s and the hiatal should be
repaired. Patients should be followed with endo-
scopyandmedicalmanagement until it is established
there is no residual or recurrent esophagitis. Any
residual Barrett’s should be retreated with PDT.
CONCLUSIONS
The only statistically significant variable affecting
survival after PDT to carcinoma of the esophagus
was the clinical stage. Analysis of each individual
stage showed the KPS was the only statistically
significant confounding variable and the most
significant effect occurred when the KPS was >70
for Stages III and IV. Completely obstructed hard
tumors that cannot be dilated can be treated blindly
with PDT, and they soften by the end of treatment.
Cervical lesions are difficult to treat with the YAG
laser while the PDT diffuser tip can be inserted and
the treatment performed blindly. PDT also treats
submucosal spread that is not visible and can be
used to treat small mammary-like tumors. Debulk-
ing large tumors and treating the residual tumor
with PDT utilizes the advantages of both techni-
ques. Palliation with PDT compares favorably to
surgery for "non-curative" disease. PDT can be used
concomitantly with chemotherapy and X-ray irra-
diation and can be repeated indefinitely. Photo-
sensitivity of the skin to solar irradiation due to the
photosensitizer is more of a nuisance than a serious
problem for most of these patients.
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